Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 1/20 | 0.59 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.59 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 17/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7484394 | 0.87 | PKN1 (0.60) | PKN1PKN2RIPK1PARP1PLA2G2A | |
| SCHEMBL1933246 | 0.85 | PARP1 (0.69) | PKN1PKN2PARP1PARP2 | |
| SCHEMBL7475827 | 0.84 | PKN1 (0.57) | PKN1PKN2RIPK1PARP1 | |
| SCHEMBL7966462 | 0.83 | PKN1 (0.56) | PKN1PKN2RIPK1PARP1PLA2G2A | |
| SCHEMBL1202374 | 0.82 | PKN1 (0.61) | PKN1PKN2RIPK1PARP1PLA2G2A | |
| SCHEMBL27720114 | 0.82 | KDM4E (0.57) | PKN1PKN2PARP1PARP2 | |
| SCHEMBL1170810 | 0.82 | PKN1 (0.77) | PKN1PKN2RIPK1PARP1PLA2G2A | |
| SCHEMBL7477535 | 0.81 | PARP1 (0.68) | PKN1PKN2RIPK1PARP1PLA2G2A | |
| SCHEMBL24512711 | 0.79 | PKN1 (0.61) | PKN1PKN2RIPK1PARP1PLA2G2A | |
| SCHEMBL6366339 | 0.79 | PKN1 (0.61) | PKN1PKN2RIPK1PARP1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-6316482-B1 | FOR THERAPY AND PROPHYLAXIS OF HYPERTENSION, HEART FAILURE, RENAL INSUFFICIENCY, EDEMA, ASCITES, VASOPRESSIN PARASECRETION SYNDROME, HEPATOCIRRHOSIS, HYPONATREMIA, HYPOKALEMIA, DIABETIC, CIRCULATION DISORDER, CEREBROVASCULAR DISEASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-6207693-B1 | Benzamide derivatives having a vasopressin antagonistic activity | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0946519-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998024771-A1 | BENZAMIDE DERIVATIVES HAVING A VASOPRESSIN ANTAGONISTIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | PKN1 175/4885PKN2 115/4885RIPK1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.